Driehaus Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Driehaus Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$89.6M	Buy	731,053 +10,125	+1%	+$1.06M	0.52%	60
2026 Q1	$76M	Sell	720,928 -378,242	-34%	-$33.5M	0.56%	44
2025 Q4	$96M	Sell	1,099,170 -40,684	-4%	-$3.33M	0.65%	35
2025 Q3	$75.7M	Buy	1,139,854 +382,144	+50%	+$21.7M	0.54%	54
2025 Q2	$41.9M	Buy	757,710 +522,637	+222%	+$25.1M	0.34%	99
2025 Q1	$11.4M	Sell	235,073 -104,625	-31%	-$4.38M	0.11%	227
2024 Q4	$13.1M	Sell	339,698 -105,654	-24%	-$4.61M	0.11%	217
2024 Q3	$20M	Sell	445,352 -111,483	-20%	-$4.5M	0.17%	171
2024 Q2	$19.3M	Sell	556,835 -3,695	-0.7%	-$108K	0.19%	149
2024 Q1	$16.2M	Buy	560,530 +361,841	+182%	+$9.85M	0.16%	187
2023 Q4	$4.56M	Buy	+198,689	New	+$3.48M	0.05%	270

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Driehaus Capital Management's PTGX Position: Q2 2026 in Review

Driehaus Capital Management increased its Protagonist Therapeutics (PTGX) stake by 1.4% in Q2 2026, buying an estimated $1.06M and bringing the position to 731,053 shares worth $89.6M. The position accounts for 0.52% of the portfolio, ranked #60.

Driehaus Capital Management first reported a position in PTGX in Q4 2023 and has held it in 11 quarters since. The position peaked at $96M in Q4 2025. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Driehaus Capital Management held 731,053 shares of Protagonist Therapeutics worth $89.6M as of Q2 2026.
Driehaus Capital Management bought 10,125 Protagonist Therapeutics shares in Q2 2026, an estimated $1.06M.
Protagonist Therapeutics made up 0.52% of Driehaus Capital Management's portfolio in Q2 2026, its #60 holding.
Driehaus Capital Management first reported a position in Protagonist Therapeutics in Q4 2023 and has held it in 11 quarters since.
Driehaus Capital Management's Protagonist Therapeutics position peaked at $96M in Q4 2025.
344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Driehaus Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.